Category: Parkinson's Disease: Genetics
Objective: We aimed to evaluate the association of selected polymorphisms of COMT, DRD2, ANKK1, and DAT genes and the occurrence of levodopa-induced motor complications in a large group of PD patients.
Background: The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease (PD) is still insufficiently explored.
Method: Serbian PD patients (N=234) treated with levodopa for at least two years were genotyped for the rs4680 in COMT, rs6277, rs1076560, and rs2283265 in DRD2, and rs1800497 and rs2734849 polymorphisms in ANKK1 genes. Also, a variable number of tandem repeats (VNTR) polymorphism in the DAT gene was examined.
Results: Dyskinesias were more frequent among AA rs4680 COMT carriers than AG and GG rs4680 COMT carriers. A significantly higher frequency of motor fluctuations was found in carriers of GGAAA and AGGAA ANKK1/DRD2 haplotypes compared to PD patients who were not carriers of these haplotypes. Independent predictors related to motor fluctuations were the age at PD onset, disease duration, levodopa daily doses ≥500mg, and PD severity. Independent predictors related to dyskinesias were gender, disease duration, LEDD≥900mg, PD severity, and AA genotype of the rs4680 COMT gene. AA genotype rs4680 COMT gene had a 2.8 times higher risk for dyskinesias occurrence.
Conclusion: Our results suggest a possible role of genetic factors in the development of levodopa-induced motor complications in PD. These results should be considered as positive preliminary evidence which needs to be addressed in further longitudinal studies in a larger cohort.
References: 1. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol. 2005;252: 37– 42.
2. Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord.2015;30:80–89.
3. Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G. Risk and course of motor complications in a population-based incident Parkinson’s disease cohort. Parkinsonism Relat Disord. 2016; 22:48–53.
4. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;20: S11-6.
5. Dragašević-Mišković N, Petrović I, Stanković I, Kostić V. Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opin Pharmacother. 2019¸20:219-230.
6. de Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord. 2012; 27:132-135.
7. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson’s disease, levodopa treatment response, and complications. Pharmacogenet Genomics. 2008; 18:815-821.
8. Sampaio TF, Dos Santos EUD, de Lima GDC, et al. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson’s Disease. J Clin Pharmacol. 2018;58:920-926.
9. Białecka M, Droździk M, Kłodowska-Duda G et al. The effect of monoamine oxidase B (MAO B) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson’s disease. Acta Neurol Scand. 2004;110:260-266.
10. Lee MS, Lyoo ChH, Ulmanen I, Syvanen AC, Rinne JO. Genotypes of catechol-O-methyltransferase and response to L-dopa treatment in patients with Parkinson’s disease. Neurosci Lett. 2001;298:131–134.
11. Watanabe M, Harada S, Nakamura T, Ohkoshi N, Yoshizawa K, Hayashi A, et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing off and dyskinesia in Parkinson’s disease. Neuropsychobiology. 2003;48:190-193.
12. Cheshire P, Bertram K, Ling H, et al. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson’s disease. Neurodegener Dis. 2014;13:24-28.
13. Oliveri RL, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology. 1999;53:1425-1430
14. Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology. 2001;56:1757–1759.
To cite this abstract in AMA style:
B. Radojević, N. Dragašević-Mišković, A. Milovanović, I. Petrović, M. Svetel, I. Jančić, D. Stanisavljević, O. Milićević, M. Savić, V. Kostić. The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/the-role-of-genetic-factors-in-the-occurrence-of-levodopa-induced-motor-complications-in-parkinsons-disease/. Accessed November 21, 2024.« Back to 2023 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-role-of-genetic-factors-in-the-occurrence-of-levodopa-induced-motor-complications-in-parkinsons-disease/